Tekmira Pharmaceuticals Releases Second Quarter 2007 Operating Results

FOR IMMEDIATE RELEASE: August 8, 2007

Vancouver, BC — Tekmira Pharmaceuticals Corporation ("Tekmira"; TSX:TKM) reported today in its Second Quarter 2007 operating results that it remains on track to complete all its 2007 drug development milestones and expects to have eight treatments for cancer and other diseases in human clinical trials in the next 12 to 18 months.

Tim Ruane, President and CEO of Tekmira, said key achievements during the Second Quarter included:

- An announcement April 17, 2007 by Tekmira's partner Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) that it will advance a systemically delivered RNAi therapeutic, ALN-VSP01, for the treatment of liver cancer and potentially other solid tumors. ALN-VSP01 is a combination of two small interfering RNA (siRNA) molecules, the molecules that mediate RNAi. Tekmira will manufacture ALN-VSP01 in preparation for Alnylam conducting toxicology studies. Tekmira will also be eligible to receive milestone payments as ALN-VSP01 is developed and royalties on product sales.

- Completion on May 1, 2007 of Tekmira's spin-out from Inex Pharmaceuticals Corporation and commencement of Tekmira's common shares trading on the Toronto Stock Exchange.

Ruane also said that Alnylam's leadership position in the field of RNA interference (RNAi) therapeutics was highlighted with the announcement July 9, 2007 that Alnylam had entered into a major alliance with Roche. The discovery of RNAi was recognized with the award of the Nobel Prize in 2006.

Ruane said Tekmira, through its partnerships, had three products in clinical trials at the end of the second quarter and expects up to five others that utilize the Company's technology will be in clinical trials before the end of 2008.

"Our internal clinical development program, our joint development partnerships with other companies and our strong financial position combine to place Tekmira in a leading position among development-stage Canadian biotech companies," said Ruane.

Subsequent to the end of the quarter, on August 3, 2007, Tekmira's partner Hana Biosciences Inc. (Nasdaq: HNAB) initiated a Phase 2 clinical trial evaluating Marqibo as a treatment for relapsed acute lymphoblastic leukemia.

Over the next 12-18 months, the Company expects the following milestones to be achieved for products using Tekmira's proprietary technology:

- Commencement by Hana of a Phase 3 clinical trial to evaluate Marqibo as a treatment for front-line acute lymphoblastic leukemia.
- Completion by Hana of a Phase 1 clinical trial evaluating cancer drug Alocrest (formerly INX-0125).
- Commencement by Hana of a Phase 1 clinical trial evaluating cancer drug Optisomal Topotecan (formerly INX-0076).
- Continuation of toxicology and other studies in preparation for filing by Tekmira in 2008 of an investigational new drug (IND) application for approval to evaluate INX-0167 in clinical trials. Tekmira is developing INX-0167 to stimulate the immune system to treat cancer.
- Filing of an IND by Alnylam for approval to begin clinical trials for PCS-01, an RNAi therapeutic targeting the PCSK9 gene, for the treatment of hypercholesterolemia.
- Filing of an IND by Alnylam for approval to begin clinical trials for ALN-VSP01, an RNAi therapeutic targeting the VEGF and KSP genes, for the treatment of liver cancer and, potentially, other solid tumors.
- Announcement of a gene target for the first of Tekmira's three RNAi therapeutic products included in the Alnylam partnership.

FINANCIAL RESULTS

Restructuring of Inex – Transfer of Business to Tekmira

Tekmira did not carry on any active business until April 30, 2007 when, together with Inex, its parent company at that time, it was reorganized under a Plan of Arrangement. Under the Plan of Arrangement all of Inex's business and transferable assets and liabilities and contractual arrangements, including all cash and cash equivalents, all intellectual property, products, technology and partnership arrangements were transferred to Tekmira. Inex's management team and employees are now employed by Tekmira where they have assumed the same positions they occupied in Inex. 100% of Tekmira's common shares have been distributed to Inex's common shareholders on a pro-rata basis with each shareholder of Inex receiving one common share of Tekmira for each share of Inex held.

On April 30, 2007, concurrent with and as part of the Plan of Arrangement, Inex, having no pharmaceutical assets, issued convertible debentures to a group of investors (the "Investors") for $5.3 million in cash. When the convertible debentures are converted, the Investors will hold 100% of the non-voting shares in Inex and 80% of the total number of Inex's outstanding common shares.

$5.2 million (US$4.7 million) of the cash received by Inex upon the issuance of the convertible debentures has been recorded as Additional paid-in capital. The $5.2 million was subsequently paid to certain former noteholders as discussed below. The remaining balance of the cash raised from the convertible debenture of $0.1 million will be used by Inex as working capital and was not contributed to Tekmira.

Effective May 1, 2007, Tekmira's common shares began trading on the Toronto Stock Exchange under the symbol "TKM" and the common shares of Inex ceased to trade.

As a non-recurring related party transaction between Tekmira and Inex under common control, the assets and liabilities were transferred at their carrying values using the continuity-of-interests method of accounting. For reporting purposes, Tekmira is considered to have continued Inex's pharmaceutical business and will include the historical operating results of Inex to April 30, 2007. Accordingly, for the reporting periods ended June 30, 2007, the financial statements combine the financial results for the business carried on in Inex up to April 30, 2007 with those of Tekmira from May 1, 2007 to June 30, 2007.

Tekmira continues to carry on the biopharmaceutical business of Inex, and after completion of the Plan of Arrangement, Inex was renamed 1322256 Alberta Ltd.

Purchase and settlement of the exchangeable and development notes (the "Notes")

On June 20, 2006, the Company signed a purchase and settlement agreement (the "Purchase and Settlement Agreement") with the holders of the exchangeable and development notes (the "Former Noteholders"). The Purchase and Settlement Agreement retired the exchangeable and development notes in exchange for US$2.5 million in cash, 1,118,568 Hana shares received on licensing the Company's chemotherapy products to Hana and certain contingent consideration. The balance of the contingent obligation has been adjusted as the Hana shares were released for trading and their value, as definitively determined under the Purchase and Settlement Agreement, was established.

On April 30, 2007, the Company completed a corporate reorganization and, as required under the Purchase and Settlement Agreement, paid the proceeds from the reorganization of $5.2 million (US$4.7

million) to the Former Noteholders. This payment has been recorded in the three month period ended June 30, 2007 as a loss on purchase and settlement of exchangeable and development notes.

The balance of the contingent obligation under the Purchase and Settlement Agreement as at June 30, 2007 of US$22.8 million will only change and will only be paid down with milestone or royalty payments which may be received from Hana. The Former Noteholders have no recourse to any of the Company's other assets.

Results of operations overview / For the six months ended June 30, 2007, Tekmira's net loss was $4.4 million ($0.19 per common share, basic and fully diluted) as compared to net income of $17.3 million ($0.90 per common share, basic and fully diluted) for the comparable period in 2006. For the three months ended June 30, 2007, Tekmira's net loss was $5.1 million ($0.21 per common share, basic and fully diluted) as compared to net income of $21.2 million ($1.10 per common share, basic and $1.09 per common share, fully diluted) for the comparable period in 2006.

There are a number of factors contributing to changes in the results the largest of which is the gain on the purchase and settlement of the exchangeable and development notes of $26.8 million in the second quarter of 2006 and the $5.2 million partial reversal of the gain in the second quarter of 2007.

Revenue / Revenue from research and development collaborations, licensing fees and milestone payments was $3.0 million for the second quarter of 2007 as compared to $6.1 million for the second quarter of 2006 and was $5.9 million for the first half of 2007 as compared to $6.1 million for the first half of 2006. Revenue arises from licensing and collaboration payments from partnerships with Alnylam and Hana.

Revenue is detailed in the following table:

	Three months ended		**Six months ended**	
(in millions Cdn$)	**June 30, 2007**	June 30, 2006	**June 30, 2007**	June 30, 2006
Research and development collaborations				
Alnylam	**$ 0.6**	$ 0.4	**$ 1.0**	$ 0.4
Hana	**0.1**	0.5	**0.3**	0.5
Total research and development collaborations	**$ 0.7**	$ 0.9	**$ 1.3**	$ 0.9
Licensing fees and milestone payments				
Alnylam licensing fees:				
2006 licensing options amortization	**$ 0.1**	$ 0.1	**$ 0.2**	$ 0.1
Up-front payment amortization	**1.2**	-	**2.3**	-
Hana up-front licensing fee amortization	**1.0**	5.0	**2.0**	5.0
Total licensing fees and milestone payments	**$ 2.3**	$ 5.1	**$ 4.5**	$ 5.1

Alnylam revenue / On March 25, 2006, Tekmira signed an exclusive research collaboration agreement with Alnylam to evaluate Alnylam's RNAi therapeutics with Tekmira's systemic lipid-based technology. On January 8, 2007, Tekmira entered into a licensing and expanded collaboration agreement with Alnylam giving them a worldwide exclusive license to Tekmira's lipid-based delivery formulation technology for the discovery, development, and commercialization of RNAi therapeutics, and expanding the existing research and manufacturing alliance. As covered earlier in this discussion, the financial

terms of the agreement include a minimum of US$2.0 million in research and development collaboration funding in both 2007 and 2008 and this revenue is being recognized based on the time spent by the Company's scientific staff on Alnylam research and development projects.

Under the agreement, Tekmira is also providing contract manufacturing services to Alnylam. The cost of manufacturing batches of drugs for Alnylam is being recorded as inventory. Revenue from manufacturing services will be recognized when Alnylam accepts each production batch and related expenses will be recorded at that time.

Under the January 8, 2007 agreement with Alnylam Tekmira received an up-front licensing payment of $9.4 million (US$8.0 million) which is being amortized to revenue on a straight-line basis over the period ending December 31, 2008 which is the period that it is expected the Company will provide research support to Alnylam. As a result, $1.2 million and $2.3 million of the Alnylam up-front payment is included in licensing fees and milestone payments revenue in the first quarter and first half of 2007 respectively. A milestone payment to the University of British Columbia of $0.9 million, representing 10% of the up-front licensing payment from Alnylam, is being amortized to research and development expenses to the period ending December 31, 2008.

Hana revenue / On May 6, 2006, Tekmira signed a number of agreements with Hana including an agreement to issue worldwide licenses (the "License Agreement") for its targeted chemotherapy products, Marqibo®, Alocrest™ and Optisomal Topotecan. Under the License Agreement, Hana paid a non-refundable up-front cash payment of $1.7 million (US$1.5 million) and issued 1,118,568 Hana shares to Tekmira (together the "Up-front Payments"). The value of the Hana shares on May 6, 2006, based on a share price of $12.34 (US$11.15) was $13.8 million (US$12.5 million) giving a total of $15.5 million (US$14.0 million) in Up-front Payments.

In accordance with the Company's revenue recognition policy, the Up-front Payments were deferred and were initially being amortized on a straight line basis from April 3, 2006 to December 31, 2006 by which time Tekmira had expected to deliver substantially all of its services under the Service Agreement. After reviewing the delivery of services to Hana in the fourth quarter of 2006, the Company now expects to deliver substantially all of its services by the end of 2007 so has extended the amortization of the Up-front Payments, effective October 1, 2006, to December 31, 2007. As a result, $1.0 million and $2.0 million of the Hana Up-front Payments is included in licensing fees and milestone payments revenue in the second quarter and first half of 2007 and $2.1 million of the Up-front Payments is included in the June 30, 2007 balance sheet as deferred revenue.

Effective April 3, 2006, Tekmira signed a Service Agreement under which Hana is reimbursing the Company for expenses and time spent in maintaining and transferring the technology and product expertise related to the three targeted chemotherapy products. Revenue from the Service Agreement is recorded as research and development collaboration revenue.

Under the License Agreement Tekmira could receive up to an additional US$29.5 million in cash or Hana shares for development and regulatory milestones and will also receive royalties on product sales. Tekmira has agreed to pay certain of the future contingent Hana milestones and royalties to the Former Noteholders.

Expenses / Research and development / Research and development expenses decreased to $1.0 million for the second quarter of 2007 as compared to $1.2 million for second quarter of 2006 and fell to $2.2 million for the first half of 2007 as compared to $2.5 million for the first half of 2006. The decreases relate primarily to a reduction in salary expense. Tekmira's internal research and development staff numbers have increased significantly to 39 at June 30, 2007 (total staff 51) as compared to 18 (total staff 28) at June 30, 2006. However, a significant portion of the Company's research and development

salaries and its materials costs relate to Alnylam batch manufacture so have been deferred to inventory (see Alnylam revenue).

General and administrative / General and administrative expenses increased to $1.7 million for the second quarter of 2007 as compared to $1.0 million for second quarter of 2006 and $2.6 million for the first half of 2007 as compared to $2.2 million for the first half of 2006. The increases in general and administrative expenses are largely due to spin-out related professional fees and initial Toronto Stock Exchange listing fee for Tekmira.

Amortization / Amortization expense decreased to $0.1 million in the second quarter of 2007 as compared to $0.2 million for second quarter of 2006 and $0.2 million in the first half of 2007 as compared to $0.6 million for the first half of 2006. The decreases in amortization are primarily due to the full impairment of all of the Company's capitalized medical technology following the licensing of its targeted chemotherapy technology to Hana on May 6, 2006 and hence no medical technology amortization expense thereafter.

Other Income/Losses / Interest income / Interest income increased to $0.3 million for the second quarter of 2007 as compared to $0.1 million for second quarter of 2006 and $0.5 million for the first half of 2007 as compared to $0.2 million for the first half of 2006. The increases are primarily the result of an increase in average cash and cash equivalents balances.

Gain (Loss) on purchase and settlement of exchangeable and development notes / As discussed earlier, on June 20, 2006 the Company signed the Purchase and Settlement Agreement with the Former Noteholders and recorded a gain on settlement of $26.8 million.

On April 30, 2007, the Company completed a corporate reorganization and, as required under the Purchase and Settlement Agreement, paid the proceeds from the reorganization of $5.2 million (US$4.7 million) to the Former Noteholders. This payment has been recorded in the second quarter of 2007 as a loss on purchase and settlement of exchangeable and development notes.

Hereafter, the contingent obligation under the Purchase and Settlement Agreement of US$22.8 million will only change and will only be paid down with milestone and royalty payments which Tekmira may receive from Hana. Until the contingent obligation is fully repaid, milestone or royalty payments received from Hana, will be recorded in Tekmira's Statement of Operations as licensing fees and milestone payment revenue with an equal and opposite loss on purchase and settlement of exchangeable and development notes. The net effect of these transactions on the Company's net income or loss will be nil.

Foreign exchange and other gains and losses / Foreign exchange and other gains and losses showed losses of $0.5 million in the second quarter of 2007 as compared to gains of $1.7 million in the second quarter of 2006 and losses of $0.6 million in the first half of 2007 as compared to gains of $1.6 million in the first half of 2006. Foreign exchange losses in the second quarter and first half of 2007 relate largely to the adverse effect of the Canadian dollar strengthening against the US dollar and Tekmira's US denominated cash and cash equivalents and accounts receivable being in excess of its US denominated accounts payable. The Company recorded foreign exchange gains in the second quarter and first half of 2006 as in those periods the strengthening Canadian dollar, as compared to the US dollar, reduced its US dollar denominated exchangeable and development notes balance as reported in Canadian dollars. Exchange rate fluctuations will continue to create gains or losses as Tekmira's expects to continue holding US denominated cash and cash equivalents, accounts receivable and accounts payable.

Capital expenditures / Capital expenditures increased to $0.5 million in the second quarter of 2007 as compared to $0.1 million in the second quarter of 2006 and $0.9 million in the first half of 2007 as compared to $0.1 million in the first half of 2006. In the second quarter and first half of 2007 Tekmira

purchased laboratory equipment, manufacturing equipment and made partial payment towards an electronic IND filing system. The Company also upgraded its information technology hardware and software.

RISKS AND UNCERTAINTIES

Tekmira's funding needs may vary depending on a number of factors including:

- revenues earned from its partnership with Alnylam and, to a lesser extent, its Service Agreement with Hana
- decisions to in-license or acquire additional products for development, in particular for its RNAi therapeutics program
- the pace at which the Company is able to or decides to continue to expand its staffing, research and development and operations in general
- the extent to which it continues development of or can extract significant value from its technologies
- its ability to attract and retain corporate partners, and their effectiveness in carrying out the development and ultimate commercialization of its product candidates
- the decisions, and the timing of decisions, made by health regulatory agencies regarding its technology and products
- competing technological and market developments
- prosecuting and enforcing its patent claims and other intellectual property rights

Tekmira's risks and uncertainties prior to completion of the Plan of Arrangement on April 30, 2007, are discussed in further detail in Inex's Annual Information Form which can be found at www.sedar.com. As a result of the completion of the Plan of Arrangement, Inex's business and the associated risks and uncertainties have been transferred to Tekmira.

FINANCIALS

Balance Sheets

(Expressed in Canadian Dollars)		June 30 2007		December 31 2006
		Unaudited		
ASSETS				
Current assets				
Cash and cash equivalents	**$**	**22,439,397**	$	5,670,748
Accounts receivable		**1,242,574**		704,663
Inventory		**1,458,747**		-
Prepaid expenses and other assets		**133,898**		76,050
Total current assets		**25,274,616**		6,451,461
Property and equipment		**1,290,147**		582,503
	$	**26,564,763**	$	7,033,964
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)				
Current liabilities				
Accounts payable and accrued liabilities	**$**	**1,237,201**	$	1,763,523
Current portion of obligations under capital leases		**93,275**		96,855
Current portion of deferred lease inducements		**64,409**		134,777
Current portion of deferred revenue		**6,789,342**		4,781,798
Total current liabilities		**8,184,227**		6,776,953
Obligations under capital leases		**31,795**		75,728
Deferred revenue		**2,303,508**		-
Total liabilities		**10,519,530**		6,852,681
Shareholders' equity:				
Share capital		**195,340,575**		180,237,917
Additional paid-in capital		**20,396,711**		15,211,567
Deficit		**(199,692,053)**		(195,268,201)
Total shareholders' equity		**16,045,233**		181,283
	$	**26,564,763**	$	7,033,964

Statements of Operations, Comprehensive Income (Loss) and Deficit

(Expressed in Canadian Dollars)	Three months ended June 30 2007 Unaudited	Three months ended June 30 2006 Unaudited	Six months ended June 30 2007 Unaudited	Six months ended June 30 2006 Unaudited
Revenue				
Research and development collaborations	**$ 676,630**	$ 940,033	**$ 1,339,050**	$ 940,033
Licensing fees and milestone payments	**2,301,308**	5,129,431	**4,511,466**	5,140,787
	2,977,938	6,069,464	**5,850,516**	6,080,820
Expenses				
Research, development and collaborations	**1,011,323**	1,179,617	**2,174,125**	2,451,526
General and administrative	**1,662,618**	1,026,369	**2,562,636**	2,171,319
Impairment of medical technology	**-**	7,210,515	**-**	7,210,515
Amortization	**110,810**	187,089	**217,142**	620,472
	2,784,751	9,603,590	**4,953,903**	12,453,832
Income (Loss) from operations	**193,187**	(3,534,126)	**896,613**	(6,373,012)
Interest income	**297,976**	108,777	**473,005**	205,137
Interest on exchangeable and development notes	**-**	(881,194)	**-**	(1,872,729)
Gain (Loss) on purchase and settlement of exchangeable and development notes	**(5,179,000)**	26,844,179	**(5,179,000)**	26,844,179
Foreign exchange and other gains and losses	**(447,567)**	1,725,414	**(614,470)**	1,554,515
Loss on disposal of Hana Biosciences, Inc. shares	**-**	(3,069,049)	**-**	(3,069,049)
Income (loss) before income tax	**(5,135,404)**	21,194,001	**(4,423,852)**	17,289,041
Income tax		806	**-**	806
Net and comprehensive income (loss)	**(5,135,404)**	21,193,195	**(4,423,852)**	17,288,235
Deficit, Beginning of period	**(194,556,649)**	(226,191,198)	**(195,268,201)**	(222,286,238)
Discount on exchangeable and development notes	**-**	5,943,374	**-**	5,943,374
Deficit, End of period	**$ (199,692,053)**	$ (199,054,629)	**$ (199,692,053)**	$ (199,054,629)
Weighted average number of common shares				
Basic	**24,563,883**	19,283,394	**23,119,794**	19,283,394
Diluted	**24,563,883**	19,385,807	**23,119,794**	19,290,227
Income (Loss) per common share				
Basic	**$ (0.21)**	$ 1.10	**$ (0.19)**	$ 0.90
Diluted	**$ (0.21)**	$ 1.09	**$ (0.19)**	$ 0.90

Statements of Cash Flow (Unaudited)

(Expressed in Canadian Dollars)

	Three months ended		Six months ended	
	June 30 2007	June 30 2006	**June 30 2007**	June 30 2006
OPERATIONS				
Income (Loss) for the period	**$ (5,135,404)**	$ 21,193,195	**$ (4,423,852)**	$ 17,288,235
Items not involving cash:				
Amortization of property and equipment	**110,810**	(51,376)	**217,142**	142,176
Amortization of medical technology	**-**	238,465	**-**	478,305
Impairment of medical technology	**-**	7,210,515	**-**	7,210,515
Amortization of deferred lease inducements	**(35,184)**	(35,184)	**(70,368)**	(70,368)
Interest on exchangeable and development notes	**-**	881,194	**-**	1,872,729
Unrealized foreign exchange loss on exchangeable and development notes	**-**	(1,838,930)	**-**	(1,659,484)
Gain (Loss) on purchase and settlement of exchangeable and development notes	**-**	(26,844,179)	**-**	(26,844,179)
Loss on disposal of Hana Biosciences, Inc. shares	**-**	3,069,049	**-**	3,069,049
Stock-based compensation expense	**41,955**	82,002	**97,076**	311,738
Gain from sale of property and equipment	**-**	-	**-**	(10,948)
Change in deferred revenue	**(2,061,625)**	(3,199,800)	**4,311,052**	(3,199,800)
Net change in non-cash working capital	**(2,576,633)**	(345,835)	**(2,580,828)**	(1,460,255)
	(9,656,081)	359,116	**(2,449,778)**	(2,872,287)
INVESTMENTS				
Proceeds from sale of property and equipment	**-**	-	**-**	16,492
Acquisition of property and equipment	**(535,297)**	(58,002)	**(924,786)**	(76,995)
	(535,297)	(58,002)	**(924,786)**	(60,503)
FINANCING				
Issuance of common share pursuant to:				
Bought deal, net of issue costs	**-**	-	**14,917,150**	-
Exercise of options	**120**	-	**94,576**	-
Capital contribution from Inex Pharmaceuticals Corporation	**5,179,000**	-	**5,179,000**	-
Repayment of obligations under capital leases	**(23,985)**	(22,203)	**(47,513)**	(70,324)
Repayment of exchangeable and development notes	**-**	(2,790,500)	**-**	(2,790,500)
	5,155,135	(2,812,703)	**20,143,213**	(2,860,824)
Increase (decrease) in cash and cash equivalents	**(5,036,243)**	(2,511,589)	**16,768,649**	(5,793,614)
Cash and cash equivalents, beginning of period	**27,475,640**	8,890,997	**5,670,748**	12,173,022
Cash and cash equivalents, end of period	**$ 22,439,397**	$ 6,379,408	**$ 22,439,397**	$ 6,379,408

About Tekmira
Tekmira Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer and other diseases. Further information about Tekmira and this news release can be found at www.tekmirapharm.com.

Forward Looking Statements
There are forward-looking statements and information contained herein that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects," and similar expressions, and the negative of such expressions. Such forward-looking statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements and information. Such factors include, among others, Tekmira's stage of development, lack of product revenues, additional capital requirements, risks associated with the completion of clinical trials and obtaining regulatory approval to market Tekmira's products, the ability to protect its intellectual property and dependence on collaborative partners. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements or information. Tekmira disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements or information contained herein to reflect future results, events or developments, except as required by law.

Contact Information for Tekmira Pharmaceuticals Corporation

Investors
Ian Mortimer
Senior Vice President, Finance and Chief Financial Officer
Phone: 604-419-3200

Media
Nicole Rizgalla
James Hoggan & Associates Inc.
Phone: 604-742-4268
Email: nrizgalla@hoggan.com

The common shares of Tekmira are traded on the Toronto Stock Exchange under the trading symbol "TKM".